A library of recent articles, news and insights.
Will COVID Testing Be Needed When the Pandemic Ends?
With the COVID-19 vaccine being distributed and overall infection rates stabilizing, people are beginning to talk about life after the pandemic. Anxious to get back to some kind of normality, even if it means adopting a new normal that includes continued mask wearing and physical distancing, businesses are making plans to open back up.
Visby Medical’s COVID-19 PCR Point of Care Test Authorized for Use in CLIA Waived Settings
Expanding critical access to the only single-use, rapid PCR test, at the point of care.
Visby Medical speeds development of a rapid Flu-COVID PCR test designed for at-home use with BARDA funding
Visby Medical pairs speed with the accuracy of gold-standard PCR testing in a single-use device, so doctors don’t have to fight blind.
What is PCR?
PCR’s superpower lies in its super sensitivity, which enables it to sniff out even low levels of a pathogen in minutes. Here’s how it works.
Visby Medical’s Personal PCR Receives Funding from National Institute of Health, RADx Program
Visby Medical, an infectious disease diagnostic company, received funding from the National Institutes of Health as part of the organization’s Rapid Acceleration of Diagnostics (RADx) program, an initiative that aims to combat SARS-CoV-2 and increase national testing capacity for COVID-19.
Personal PCR: Rapid, Reliable, and Prolific
Personal PCR could one day become as common as the common cold. In the future, the device will deliver lab accurate results anywhere and to anyone — forever changing our relationship with diagnostics.
Visby Medical’s Personal PCR Device Receives FDA Emergency Use Authorization for Moderate-Complexity Lab Environments
Seven-year-old startup emerges from stealth mode, provides adaptable and rapid testing technology to frontline lab personnel fighting the pandemic
Visby exits stealth to bring its Personal PCR Test to the fight against COVID-19
Now that Visby has received EUA for our Personal PCR Test to be deployed in moderate-complexity CLIA-certified labs, we’re taking it to the front line of the fight against COVID-19. Each device is personal to individual patients, with results delivered to a lab technician in less than 30 minutes.
Rapid diagnostic for gonorrhea wins $19 million federal prize competition to combat antibiotic resistance
As appeared in NIH website 8/5/20
On-the-go coronavirus test maker gets $10 million NIH contract to scale up production.
Visby Medical Inc. emerged from stealth mode to secure emergency use authorization (EUA).
...the first company to receive an Emergency Use Authorization from the Food and Drug Administration for a portable PCR coronavirus test kit.
Visby Medical receives $19 million as a prize for its winning diagnostic.
Antibiotic-Sparing Gonorrhea Diagnostic Wins Federal Funding.
Visby Medical Takes on STI, COVID-19 Testing With Single-Use PCR Machine.
The palm-sized machine looks at individual point mutations and provides results in less than 30 minutes from sample to answer.
